{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.5","upperLimit":"76.9","value":"61.1"},{"groupId":"OG001","lowerLimit":"42.4","upperLimit":"80.6","value":"63.0"},{"groupId":"OG002","lowerLimit":"34.8","upperLimit":"93.3","value":"70.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Overall response rate (ORR) by Independent Review Committee (Cohorts 1, 2, 3). ORR is the percent of participants with best overall response of complete response (CR) or partial response (PR).\n\nComplete response via PET-CT:\n\n* Lymph nodes/extralymphatic: Score 1, 2, 3a with/without residual mass on 5-point scale\n* New lesions: No\n* Bone marrow: No FDG-avid disease\n\nComplete response via CT scan:\n\n* Lymph nodes/extralymphatic: Target nodes/nodal masses ≤ 1.5 cm longest transverse diameter.\n* Nonmeasured lesion: No\n* New lesions: No\n* Bone marrow: Normal\n\nPartial response via PET-CT:\n\n* Lymph nodes/extralymphatic: Score 4, 5b, reduced uptake from baseline\n* New lesions: No\n* Bone marrow: Residual uptake higher than normal, reduced from baseline\n\nPartial response via CT scan:\n\n* Lymph nodes/extralymphatic: 50% decrease in sum of diameters of \\<= 6 target measurable nodes/extranodal sites\n* Nonmeasured lesion: No\n* Organ enlargement: Spleen length decreased \\> 50%\n* New lesions: No","dispersionType":"95% Confidence Interval","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"}],"paramType":"NUMBER","populationDescription":"All participants in the JCAR017 treated set. Prespecified to be reported for cohorts 1,2, and 3 only.","reportingStatus":"POSTED","timeFrame":"From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)","title":"Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3","type":"PRIMARY","unitOfMeasure":"Percent of Participants"}